Grand Rounds

Wisconsin Psychiatric Institute & Clinics
“Commons” Room 1616
6001 Research Park Blvd, Madison, WI 53719

About

The Psychiatry Grand Rounds program is designed to educate faculty and trainees, as well as Madison area professionals and members of the public, and to foster opportunities for collaboration. Every two months, a distinguished guest speaker is invited to WisPIC to give a lecture, facilitate discussions with trainees, meet with faculty, and form valuable connections with members of the department.

Grand Rounds are open to the public and anyone is welcome to attend. Continuing Medical Education units (CME’s) are available to attendees.

Journal Clubs

On the Wednesday before each talk, there will be a Journal Club from 1:00 – 2:00pm in the HERI Classrooms.

These pre-talk Journal Clubs provide an opportunity for trainees and faculty to become familiar with the guest lecturer’s work. Guest faculty have selected 3 publications related to the topic of their talk. This page contains links to the reading list where you can view and download the papers. CME credit is available for journal club participants as well.

Post-Talk Discussion

All trainees are invited to attend a discussion session and lunch with the guest lecturer following the Grand Rounds talk, from 1:30-2:15pm. This gives trainees an opportunity to ask questions related to research methods, clinical applications, public policy, advocacy, or career development. All Psychiatry residents, fellows, post-docs,  graduate students, and clinical psychology interns are invited to attend – however, you must register in advance. To RSVP,  please email Jennifer Noll with your name, affiliation to the department, and any dietary restrictions: jnoll3@wisc.edu

JANUARY 31 @ 8:00 AM – 9:00 AM
WisPIC Room 1616 | 6001 Research Park Blvd

SOCIAL MEDIA AND ADOLESCENT MENTAL HEALTH

Megan Moreno, MD, MSED, MPH
Academic Division Chief of General Pediatrics and Adolescent Medicine Division
Vice Chair of Digital Health
Principal Investigator, SMAHRT
Department of Pediatrics
University of Wisconsin-Madison


Dr. Megan Moreno, MD, MSEd, MPH is the principal investigator (PI) of the Social Media and Adolescent Health Research Team (SMAHRT). Her research team is within the Department of Pediatrics at the University of Wisconsin-Madison. Dr. Moreno is the Academic Division Chief of General Pediatrics and Adolescent Medicine Division, and Vice Chair of Digital Health in the Department of Pediatrics. She is a Professor of Pediatrics and Adjunct Professor of Educational Psychology at the University of Wisconsin-Madison.

Dr. Moreno received her MD degree from George Washington University School of Medicine. She completed a residency in Pediatrics at the University of Wisconsin-Madison, during that time she also completed a Masters Degree in Education. She completed a fellowship in Adolescent Medicine at the University of Washington, during that time she also completed a Masters Degree in Public Health.


Learning objectives:

  1. Understand the current state of the field regarding associations between social media and adolescent mental health
  2. Learn two measurement approaches in assessing social media use
  3. Understand proposed mechanisms for the relationship between social media and adolescent mental health
  4. Learn about several current national efforts to improve adolescent mental health and technology use
  5. Consider how to approach social media use with patients

MARCH 27 @ 8:00 AM – 9:00 AM
WisPIC Room 1616 | 6001 Research Park Blvd

Pediatric Bipolar Disorder:
Clues for Early Identification and Prevention

*** Part of the Briskey Family Bipolar Lecture Series ***

 


Kiki D. Chang, MD is a Psychiatrist in private practice in Palo Alto, CA. He is a former Professor of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine, Division of Child Psychiatry. He is also former Director of the Pediatric Bipolar Disorders Clinic, where he specialized in pediatric psychopharmacology and treatment of depression and bipolar disorder in children and adolescents. Dr. Chang also previously directed the Pediatric Psychopharmacology and Advanced Pediatric Psychopharmacology courses at Stanford.

Dr. Chang graduated cum laude from Princeton University and received his M.D. from the Tufts University School of Medicine. He completed his general psychiatry residency at the University of Cincinnati and his child psychiatry fellowship at Stanford University. After a postdoctoral research fellowship, Dr. Chang joined the Stanford faculty in 1999.

Dr. Chang is the recipient of the Eli Lilly Pilot Research Award from the American Academy of Child and Adolescent Psychiatry, the Klingenstein Third Generation Foundation Fellowship in Child and Adolescent Depression, and the 2003 American Psychiatric Association/AstraZeneca Young Minds in Psychiatry Award. He has been the recipient of two NARSAD Young Investigator Awards and has received a 5-year Career Development Award from the National Institutes of Health.

As Director of the Pediatric Bipolar Disorders Program, Dr. Chang conducts research into various facets of bipolar disorder. He is currently conducting phenomenologic, biologic, pharmacologic, and genetic studies of bipolar disorder in adults and children. These studies include brain imaging (MRI, MRS, fMRI) and medication trials. He is particularly interested in detecting prodromal bipolar disorder in children who might then be treated to prevent the development of full bipolar disorder. To do this, he has been studying children of parents with bipolar disorder who are at high risk for developing the disorder themselves.

Dr. Chang is the author of numerous papers and book chapters regarding bipolar disorder and pediatric psychopharmacology and has presented widely at national and international scientific conferences and meetings.

Additional Information about Kiki Chang, MD:


Talk Description:

Bipolar disorder (BD) is a chronic, debilitating illness with a lifetime worldwide prevalence of 2.4% and more disability-adjusted life-years lost than major neurological conditions or cancer.  Children with BD have a more severe course of illness with high relapse, recurrence, psychosocial impairment, substance use, and suicide at twice the rate of attempted suicides when compared to individuals with unipolar depression. Identification and recognition of symptoms that predate BD in youth would aid in early intervention and prevention efforts.  This presentation will discuss the clinical presentation of early and fully developed BD in youth, and discuss early intervention efforts so far to treat youth with early forms of BD to prevent development of full BD in their lifetime.

Learning objectives:

  1. Accurately understand the early presentations of bipolar disorders in youth.
  2. Consider alternate diagnoses for youth with irritability and mood difficulties
  3. Discuss approaches to identifying and treating youth at high risk for bipolar disorder

Reading List: 

  1. Family-focused Therapy for Symptomatic Youths at High Risk for Bipolar Disorder
  2. A Pharmacologic Algorithm for Youth Who Are at High Risk for Bipolar Disorder

 

JUNE 12 @ 12:00 PM – 1:15 PM
WisPIC Room 1616 | 6001 Research Park Blvd

 

THE MEDIA, MISINFORMATION, AND MENTAL HEALTH:
 PROACTIVE SOCIAL ADVOCACY FROM HASHTAGS TO SELF MAGAZINE AND EVERYTHING IN BETWEEN

Jessica “Jessi” Gold, MD, MS
Assistant Professor
Department of Psychiatry
Washington University in St. Louis

 


Jessica (“Jessi”) Gold, MD, MS, is an Assistant Professor in the Department of Psychiatry at Washington University in Saint Louis School of Medicine. She splits her clinical time between the Habif Health and Wellness Center and outpatient psychiatry at Barnes Jewish Hospital. She also teaches and mentors students and trainees, and is a regular writer for many media outlets.

Dr. Gold is a graduate of the University of Pennsylvania with a B.A. and M.S in Anthropology and a graduate of the Yale School of Medicine. She completed her residency training in Adult Psychiatry at Stanford University where she served as chief resident from 2017-2018. She has received numerous awards and accolades for her many contributions in the areas of mental health and psychiatry. She is a nationally recognized expert and speaks at national conferences, is interviewed regularly for news outlets, and consults for publishing and media.

Dr. Gold’s areas of interest are in college mental health, women’s mental health and gender equity, physician wellness, medical education, and the between popular media, stigma, and psychiatry. While she has published frequently in the more “traditional” methods of research papers and academic publications, she has also enjoyed teaching about mental health topics and decreasing stigma through writing for popular press outlets. She has been featured in, among others, Self, InStyle, Glamour, and the HuffPost. Some of her favorite articles have included writing about Judge Aquilina’s handling of the Larry Nassar case and its importance for survivors, educating about how to prepare for psychotherapy, and writing first person accounts of sexual harassment in healthcare for the InStyle launch of TIME’S UP Healthcare. Through her advocacy, she has forged connections with other inspirational women in medicine that led to many collaborations on popular media, from interviews, to podcasts, to articles. Two such examples include her interview of New York Time’s Best Selling Author, Dr. Jen Gunter, about her book for InStyle, and writing a piece on the illusory truth effect in the false link between gun violence and mental illness for TIME with Dr. Megan Ranney. It also led to the formation of TIME’S UP Healthcare, for which she serves on the steering committee and is a founding member.

In addition to her writing, Dr. Gold has presented on media as a tool for advocacy, leadership, and a way to combat misinformation nationally. She is very active on social media, particularly twitter (@drjessigold), and was named one of Medscape’s top 20 physician influencers on social media in 2019. She believes in using this medium to connect with and educate her patients on issues surrounding psychiatry and other mental health topics and to put a face to psychiatry that can help destigmatize and humanize the field.


Mental health is often on the front page of newspapers, the lead story on social media feeds, or the focus of a television episode or movie. These stories tend to be sensational or carry with them significant biases, slants, and sometimes outright falsehoods. We must do a better job with the journalists and those who read the news. We can at the same time strive to communicate more effectively to our patients, their family members, and the public. ThisGrand Rounds will look at the ways the media landscape has changed for mental health using examples of both misinformation and successes, but will go one step further and using examples from her own experiences (from gun violence to celebrity overdoses), Dr. Gold will discuss potential ways for psychiatrists to respond as advocates in real time. As just one example of a way a psychiatrist can use social advocacy to combat shame and stigma, she will share some of her lessons learned as a full-time academic, but also a top 20 social media influencer according to Medscape, Co-Founder of TIME’S UP Healthcare, and writer for TIME, the HuffPo, and Self, among other outlets.

Learning objectives:

  1. The learner will understand sources of information on mental health
  2. The learner will describe ways to respond to mental health in the media
  3. The learner will be asked to consider joining in advocacy in social media and popular press

Reading List:

1. Media-Related Education in Psychiatry Residency Programs
2. Here’s What I Tell My Patients Who Are Worried About ‘Antidepressant Withdrawal’ (Self.com)
3. The Dangers of Linking Gun Violence and Mental Illness (Time.com)
4. Is There an Opioid Overdose on Board? (addictionhope.com)

 

JULY 24 @ 12:00 PM – 1:15 PM
WisPIC Room 1616 | 6001 Research Park Blvd

Adverse Childhood Experiences and the Science of Risk and Resilience

Joan Kaufman, PhD
Director of Research,
Center for Child and Family Traumatic Stress
Kennedy Krieger Institute


 

Joan Kaufman, Ph.D. is Director of Research at the Center for Child and Family Traumatic Stress at Kennedy Krieger Institute.  She also holds appointments in the Department of Psychiatry and the School of Public Health at Johns Hopkins.

Dr. Kaufman received her Ph.D. in Clinical Psychology from Yale University where she served on faculty in the Department of Psychiatry from 1998-2015.  In 2015 she was recruited to Baltimore to serve as Director of Research at the Center for Child and Family Traumatic Stress at Kennedy Krieger Institute.  She also holds an appointment as a Professor of Psychiatry at Johns Hopkins School of Medicine and in the division of Mental Health at Johns Hopkins Bloomberg School of Public Health.

Dr. Kaufman’s research is in the area of child abuse and neglect, spans from neurobiology to social policy, and uses tools from psychology, genetics, and neuroscience to understand resilience and mechanisms of disease risk associated with early adversity. She has received consistent funding from the National Institute of Health for her research, and has published over 100 peer-reviewed professional articles and book chapters.  She also authored the book Broken Three Times: A Story of Child Abuse in America (Oxford University Press; https://www.amazon.com/Broken-Three-Times-Story-America/dp/0199399158), which is a narrative non-fiction story that follows one family through the child welfare system, with each chapter providing launching points for discussing state-of-the-art policy, practice, and scientific updates.   Dr. Kaufman is also first author on paper-and-pencil KSADS child psychiatric diagnostic interview which has been translated into more than 30 languages, and served as co-Principal Investigator on the grants funded to update the KSADS to a web-based computer-administered format.  As one of the principal developers of the KSADS, Dr. Kaufman has served as a consultant on numerous federally-funded and industry-sponsored child psychiatric clinical trials.

Dr. Kaufman’s research focuses on two areas of investigation:

1) Research on risk and resilience in maltreated children; and
2) Child psychiatric assessment and studies in support of the National Institute of Mental Health’s Research Domain Criteria (RDoC) initiative which aims to develop the necessary database to derive a new psychiatric nomenclature informed by neuroscience, genetics, and psychology.

These two lines of research are synergistic and interrelated, with the study of maltreated individuals having a number of advantages for the RDoC project, including: the study of a subset of patients that are frequently treatment resistant to standard clinical interventions; examination of a relatively homogenous sample with the onset of psychopathology proposed to be associated with stress-related mechanisms; and well-established relevant animal models to facilitate translational research.

Our investigations utilize clinical assessment, neuroimaging (e.g., structural, fMRI fear conditioning paradigm, resting state connectivity), and genetics (e.g., polymorphisms, epigenetic markers) research methods, with the goal of understanding the effects of early adversity on later development and factors that modify outcomes. Our program of research with maltreated children is broad, with a focus that spans from neurobiology to social policy.

Interview: 
https://www.kennedykrieger.org/stories/potential-magazine/winter-2015/question-and-answer-talking-trauma-early-childhood-trauma-stress


Learning objectives:

  1. __
  2. __
  3. __

Reading List:

  1. __
  2. __
  3. __

September 18 @ 12:00 PM – 1:15 PM
WisPIC Room 1616 | 6001 Research Park Blvd

Speaker/Topic TBA

This Grand Rounds talk will follow the annual Greenfield Memorial Lecture (held on Thursday, September 17 from 5:00-6:30pm)

NOVEMBER 13 @ 12:00 PM – 1:15 PM
WisPIC Room 1616 | 6001 Research Park Blvd

TITLE TBA 

Samantha Meltzer-Brody, MD, MPH
Assad Meymandi Distinguished Professor and Chair
Director, UNC Center for Women’s Mood Disorders
UNC School of Medicine


Dr. Samantha Meltzer-Brody, MD, MPH, is the Assad Meymandi Distinguished Professor and Chair of the Department of Psychiatry in the UNC School of Medicine. She also serves as the Director for the UNC Center for Women’s Mood Disorders.

Her current research efforts are focused primarily on Perinatal Depression and she is currently funded by multiple NIH grants to investigate epidemiologic, genetic, and other biomarker models of perinatal depression. She established the international postpartum depression consortium (PACT) and is the co-I of the PPD ACT app, a smart phone study that is a large international genetic study of postpartum depression and postpartum psychosis. Dr. Meltzer-Brody and colleagues also investigate novel treatment options for depression in perinatal women and she is the academic PI for the brexanolone clinical trials. She also collaborates with colleagues on global health efforts including perinatal mental health in Malawi, Africa. Dr. Meltzer-Brody has been named one of the “Top 10 Women in Medicine” from the Triangle Business Journal and is the 2016 recipient of the North Carolina Psychiatric Association Eugene Hargrove Award and the 2015 Arnold Kaluzny Distinguished Alumni Award, from Public Health Leadership Program of the UNC School of Public Health

She is also the founder of the Taking Care of Our Own Program, a resource for UNC School of Medicine and Health Care employees.


Learning objectives:

  1. __
  2. __
  3. __

Reading List: 

  1. __
  2. __
  3. __


Accreditation Statement

In support of improving patient care, the University of Wisconsin-Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


Credit Designation Statement
:

The University of Wisconsin-Madison ICEP designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.1 CEUs or 1.0 hour.

 

Archive

This is an accordion element with a series of buttons that open and close related content panels.

Karen J. Parker, PhD

ADVANCES IN DETECTING AND TREATING AUTISM

NOVEMBER 15 @ 12:00 PM – 1:15 PM
WisPIC Commons Room 1616
6001 Research Park Blvd

Karen J. Parker, PhD
Associate Professor
Director, Social Neurosciences Research Program
Department of Psychiatry and Behavioral Sciences
Stanford University School of Medicine


Dr. Parker is an Associate Professor of Psychiatry and Behavioral Sciences at Stanford University where she directs the Social Neurosciences Research Program. Dr. Parker’s research expertise is the biology of social functioning, with a particular interest in oxytocin and vasopressin signaling pathways. Her preclinical research program focuses on developing novel animal models of social impairments; her clinical research program encompasses biomarker discovery and therapeutic testing in patients with autism and other brain disorders.

Dr. Parker received her undergraduate and graduate degrees from the University of Michigan and completed postdoctoral training at Stanford University. Dr. Parker joined the Stanford faculty in 2007. She is an Affiliate Scientist at the California National Primate Research Center, a Member of the American College of Neuropsychopharmacology, and a Kavli Fellow of the US National Academy of Sciences. Dr. Parker’s research program has been supported by multiple funding agencies including the NIH, Simons Foundation, and NARSAD. Dr. Parker serves on the Editorial Board of Psychoneuroendocrinology, and on various national (e.g., NIH and NSF) and international (e.g., Medical Research Council) grant review committees and scientific panels.

Dr. Parker was born in Boulder, CO and grew up in suburban Chicago, IL. She lives in the San Francisco Bay Area with her husband (a high-tech executive), three children, and an Australian shepherd.

Reading List:

  1. Cerebrospinal Fluid Vasopressin and Symptom Severity in Children with Autism
  2. A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism
  3. Arginine vasopressin in cerebrospinal fluid is a marker of sociality in nonhuman primates
  4. Early Predictors of Impaired Social Functioning in Male Rhesus Macaques

Charles B. Nemeroff, MD, PhD

Prediction of Disease Vulnerability and Treatment Response in Mood Disorders and PTSD: Personalized Medicine in Psychiatry

Grand Rounds | Friday, September 13 | 12:00pm

Additional Talk:
Greenfield Memorial Lecture & Reception:
Progress in Suicide Prevention
Thursday,
September 12 | 5:3opm

WisPIC Commons Room 1616
6001 Research Park Blvd

Charles B. Nemeroff, MD, PhD
Chair and Professor of Psychiatry
Director, Institute for Early Childhood Adversity Research
University of Texas at Austin – Dell Medical School

Learning Objectives

  • To understand the principles of personalized medicine as applied to mood and anxiety disorders.
  • To understand the role of Genome Wide Association Studies (GWAS), candidate gene approaches, transcriptomics, epigenetics, and proteomics in predicting disease treatment response in mood and anxiety disorders.
  • To understand the potential for functional brain imaging for predicting treatment response in mood and anxiety disorders.
  • To understand the role of gene-environment interactions, particularly early life trauma, in predicting treatment response in mood disorders.

Charles B. Nemeroff, MD, PhD, is a Professor of Psychiatry and Acting Chair of the Department of Psychiatry. He is also Associate Chair of Research, and the Director of the Institute for of Early Life Adversity Research at Dell Medical School at the University of Texas at Austin.

He received his MD and PhD (Neurobiology) degrees from the University of North Carolina UNC) School of Medicine in Chapel Hill, North Carolina. After psychiatry residency training at UNC and Duke University, he held faculty positions at Duke University and was Chair of the Department of Psychiatry and Behavioral Sciences at Emory University for 18 years before relocating to the University of Miami in 2009.

He has served as President of the American College of Psychiatrists (ACP) and the American College of Neuropsychopharmacology (ACNP) and sits on the Scientific Advisory Board and Board of Directors of the American Foundation for Suicide Prevention (AFSP) and the Anxiety and Depression Association of America (ADAA).

He has received a number of research and education awards including the Kempf Award in Psychobiology, the Samuel Hibbs Award, Research Mentoring Award,Judson Marmot Award and the Vestermark Award from the American Psychiatric Association (APA), the Mood Disorders Award, Bowis Award and Dean Award from the ACP and the Julius Axelrod Award for mentoring from the ACNP. He was elected to the Institute of Medicine (now the National Academy of Medicine) of the National Academy of Sciences in 2002.

He has been named Alumnus of the Year from the University of North Carolina (UNC) and from the UNC Medical School. He received the Doctorate Honoris Causa from Maimonides University in Buenos Aires in 2015.

His research has focused on the pathophysiology of mood and anxiety disorders with a focus on the role of child abuse and neglect as a major risk factor. He has also focused on the role of mood disorders as a risk factor for major medical disorders including heart disease, diabetes and cancer. He has published more than 1100 research reports and reviews.

He has served on the Mental Health Advisory Council of NIMH and the Biomedical Research Council for NASA. He is the co-editor in chief (with Alan F. Schatzberg, MD.) of the Textbook of Psychopharmacology, published by the APA Press, now in its Fifth Edition.

His research is currently supported by grants from the NIH.

Reading List: 
1. The Holy Grail of Psychiatry (2015) 81-89
2. Understanding Depression – Contemporary Issues (2017) 21, 245-261
3. Psychosomatic Medicine (2014) 76, 445-451

 

Heather C. Abercrombie, Ph.D.

NEUROCOGNITIVE SENSITIVITY TO CORTISOL IN DEPRESSION

AUGUST 23 @ 12:00 PM – 1:15 PM
WisPIC Commons Room 1616
6001 Research Park Blvd

Heather C. Abercrombie, Ph.D.
Associate Professor (CHS)
University of Wisconsin-Madison
School of Medicine and Public Health
Department of Psychiatry


Many individuals with depression show “glucocorticoid resistance,” which reflects systemic and cellular insensitivity to the stress-related hormone cortisol.  However, the neural and psychological relevance of glucocorticoid resistance is unknown. This is a huge gap in our knowledge, because basic research shows that cortisol has potent yet variable effects on psychological function. Our research addresses this knowledge gap, and we have shown that glucocorticoid resistance is related to negatively biased emotional memory and related neural circuitry. Importantly, we have also shown that cortisol augmentation ameliorates negative memory bias in depression, particularly in glucocorticoid resistant individuals. Taken together, these findings suggest that glucocorticoid resistance is related to core psychological features of depression, and that boosting cortisol signal may be psychologically beneficial in glucocorticoid resistant individuals with depression.

Reading List:

  1. Neural Signaling of Cortisol, Childhood Emotional Abuse, and Depression-Related Memory Bias
  2. Alterations in Systemic and Cognitive Glucocorticoid Sensitivity in Depression
  3. Childhood Emotional Abuse Moderates Associations Among Corticomotor White Matter Structure and Stress Neuromodulators in Women With and Without Depression

 

Anna Ratzliff, MD, PhD

IMPLEMENTING COLLABORATIVE CARE:
TRANSLATION FROM RESEARCH TO REAL WORLD

JUNE 28 @ 12:00 PM – 1:15 PM
WisPIC Commons Room 1616
6001 Research Park Blvd

 

Anna Ratzliff, MD, PhD
Associate Professor
Depression Therapy Research Endowed Professorship
Director, AIMS Center
Director, UW Integrated Care Training Program

Learning Objectives:
1)      List common barriers and facilitators to collaborative care implementation.
2)      Describe five phases to implementation of collaborative care.
3)      Name common factors influencing the sustainability of collaborative care.

This lecture will provide a brief overview of the collaborative care model (CoCM) and review current thinking about implementation of this approach to deliver mental health treatment in primary care settings.  An approach to the five phase of implementation will be discussed including common barriers and facilitators.


Dr. Anna Ratzliff is a national expert on collaborative care and specifically, on training teams to implement and deliver mental health treatment in primary care settings. Her passion for translating complex research ideas into practical real-world applications began when she received her MD and PhD in Anatomy and Neurobiology as part of the Medical Scientist Training Program at the University of California at Irvine.  She currently is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington where she has developed expertise in suicide prevention training, mental health workforce development, adult learning best practices, and mentorship. Dr. Ratzliff is the Director of the AIMS Center (Advancing Integrated Mental Health Solutions), is the Director of the UW Integrated Care Training Program for residents and fellows, and leads a national collaborative care training program for the American Psychiatric Association’s Transforming Clinical Practices Initiative grant. For more information on collaborative care please visit the AIMS Center Website (aims.uw.edu), the UW Integrated Care Training Program (ictp.uw.edu).

Reading List:

  1. Financing for Collaborative Care – A Narrative Review
  2. Effective Implementation of Collaborative Care for Depression: What is Needed?
  3. Sustainability of collaborative care management for depression in primary care settings with academic affiliations across New York State
  4. Tele-Behavioral Health, Collaborative Care, and Integrated Care: Learning to Leverage Scarce Psychiatric Resources Over Distance, Populations, and Time

Boris Birmaher, MD

PREDICTING THE DEVELOPMENT OF BIPOLAR DISORDER AND MOOD RECURRENCES – TOWARD PERSONALIZED PSYCHIATRY

*** Part of the Briskey Family Bipolar Lecture Series ***

APRIL 19 @ 12:00 PM – 1:15 PM
WisPIC Commons Room 1616
6001 Research Park Blvd

 

Boris Birmaher, MD
Endowed Chair in Early Onset Bipolar Disease and Professor of Psychiatry
Director, Child and Adolescent Bipolar Spectrum Services
Co-Director, Psychiatry Research Pathway Program
University of Pittsburgh

 

 

 

 

 


Learning objectives:

  1. To describe the prodromal symptoms of bipolar disorder
  2. To describe the course and outcome of bipolar disorder in youth and the factors associated with increases risk for recurrences
  3. To describe the use of “risk calculators” to predict “personalized” risk to develop bipolar disorder as well as the risk of recurrences.

Dr. Birmaher is the Endowed Chair in Early Onset Bipolar Disease and Professor of Psychiatry at the University of Pittsburgh, School of Medicine and serves as the Co-Director of the Psychiatry Research Pathway program and the Director of the Child and Adolescent Bipolar Spectrum Services.  He received his medical degree from Valle University in Cali, Colombia; completed training in general psychiatry at the Hebrew University in Jerusalem, Israel, and child psychiatry at Columbia University, New York.

Dr Birmaher is a leader in the study and treatment of pediatric mood and anxiety disorders. In addition, his research has concentrated in describing the predictors, risk factors, course and treatment of childhood-onset bipolar disorder.  Throughout his career, he has served as the Principal, Co-Principal or co-investigator for over 25 federally-sponsored research grants and projects.  He has authored or co-authored more than 430 publications, numerous book chapters as well as his own book, New Hope for Children and Teens with Bipolar Disorder.  Dr. Birmaher has been the recipient of numerous awards over the years including the Colvin Prize for Outstanding Achievement in Mood Disorders Research in 2013 and the Ittleson Award for Research in Child and Adolescent Psychiatry in 2014.  In 2018, he received the Gerald L Klerman Senior Investigator Award and the Lifelong Fellow Award from the American Psychiatric Association. For four years and until 10/2018 he was the Program Chair of the American Academy of Child and Adolescent Psychiatry and recently was named Counselor-At-Large of the same association. Through his research, clinical and mentoring activities, Dr. Birmaher has increased our understanding of the risk factors for mood and anxiety disorders, developed and implemented innovative treatments to improve the lives of patients and their families, and trained the next generation of educators, clinicians and researchers.

Reading List: 

  1. Assessment of a Person-Level Risk Calculator to Predict New-Onset Bipolar Spectrum Disorder in Youth at Familial Risk
  2.  Longitudinal Trajectories and Associated Baseline Predictors in Youths With Bipolar Spectrum Disorders
  3.  A Risk Calculator to Predict the Individual Risk of Conversion From Subthreshold Bipolar Symptoms to Bipolar Disorder I or II in Youth

Conor Liston, MD, PhD

NEUROIMAGING BIOMARKERS FOR DIAGNOSING NEUROPHYSIOLOGICAL SUBTYPES OF DEPRESSION AND PREDICTING TREATMENT RESPONSE

MARCH 8 @ 12:00 PM – 1:15 PM
WisPIC Commons Room 1616
6001 Research Park Blvd

Conor Liston, MD, PhD
Assistant Professor of Neuroscience
Brain and Mind Research Institute
and Department of Psychiatry
Weill Cornell Medicine

 


Conor Liston, MD, PhD is an Associate Professor of Neuroscience and Psychiatry in the Feil Family Brain and Mind Research Institute and the Department of Psychiatry at Weill Cornell Medicine. The long-term goals of his research program are to define mechanisms by which prefrontal cortical brain circuits support learning, memory, and motivation, and to understand how these functions are disrupted in depression, addictions, and other stress-related psychiatric disorders. To this end, experiments in his lab integrate optogenetic tools and genetically encoded calcium indicators with two-photon imaging and functional MRI, and his team is actively developing new methods for quantifying prefrontal cortical microcircuit dynamics in genetically defined neuronal subtypes. They are also developing novel neuroimaging tools for informing psychiatric diagnosis in human populations and predicting treatment response to transcranial magnetic stimulation (TMS) and other neurostimulatory antidepressant interventions.

Dr. Liston graduated summa cum laude from Harvard College in 1998, and received his PhD and MD from The Rockefeller University and Weill Cornell Medicine in 2007 and 2008, respectively, where he was supported by a Paul and Daisy Soros Fellowship for New Americans. He subsequently completed his residency in psychiatry at NewYork–Presbyterian Hospital and postdoctoral training at Stanford University. He returned to Weill Cornell as an Assistant Professor in 2014. His research has been recognized with awards from the Klingenstein-Simons Foundation Fund, the Rita Allen Foundation, the Dana Foundation, the Doris Duke Charitable Foundation, and the One Mind Institute. Dr. Liston is also a clinically active psychiatrist specializing in the management of treatment-resistant mood disorders.

Reading List: 
1.Circadian glucocorticoid oscillations promote learning-dependent synapse formation and maintenance

2.Resting-state connectivity biomarkers define neurophysiological subtypes of depression

 

Melissa DelBello, MD, MS

melissa-delbelloMelissa DelBello, MD, MS

Friday, November 30, 2018

Neuropharmacology of Bipolar Disorder in Youth

*** Part of the Briskey Family Bipolar Lecture Series ***

Melissa Delbello, MD, MS, has served as professor and chair of the Department of Psychiatry and Behavioral Neuroscience since 2014. She joined the University of Cincinnati College of Medicine faculty in 2000 as an assistant professor of psychiatry and pediatrics. Dr. DelBello has served in several leadership roles in the Department of Psychiatry and Behavioral Neuroscience, including vice chair of clinical research since 2007 and co-director of the Division of Bipolar Disorders Research since 2004. She has also been co-director of the Mood Disorders Center at the UC Gardner Neuroscience Institute. A nationally recognized expert on child and adolescent mood disorders, Dr. DelBello has lectured and published extensively on bipolar disorder and served as principal or co-investigator of several NIH grants. She has been a member of the Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section of the Center for Scientific Review at the National Institutes of Health since 2009, most recently serving as chairperson for a term running from July 2012 through June 2014. Since 2012 she has chaired the Research Committee of the American Academy of Child and Adolescent Psychiatry. At UC Medical Center, she has served as medical director of the Resident Mood Medication Clinic since its launch in September 2013. She is co-director of the Mood Disorders Program at Cincinnati Children’s Hospital Medical Center. Dr. DelBello is a fellow of the American Academy of Child and Adolescent Psychiatry and also holds membership in the American Psychiatric Association, International Society for Bipolar Disorders and American College of Neuropsychopharmacology. A native of New York City, Dr. DelBello received her bachelor of science degree with honors from Cornell University and her medical degree with honors from the University of Rochester School of Medicine. She completed residencies in psychiatry at Cornell Medical Center (1995-96) and the UC College of Medicine (1996-98). In addition, she holds a master’s in epidemiology and biostatistics from UC.

Reading List: 

  1. The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research.
  2. Prediction of lithium response in first-episode mania using the LITHium Intelligent Agent (LITHIA): Pilot data and proof-of-concept.
  3. Neurofunctional Differences Among Youth With and at Varying Risk for Developing Mania.

 

Daniel Pine, MD

pine headshot

Daniel Pine, MD

Thursday, September 13

Using Neuroscience to Inform Clinical Thinking in Pediatric Anxiety

*** Dr. Pine will also be presenting the Greenfield Memorial Lecture on Wednesday, September 12th from 5:30-7pm***

Dr. Daniel Pine is Chief, Section on Development and Affective Neuroscience, in the National Institute of Mental Health Intramural Research Program. Dr. Pine moved to this position in 2000, after 10 years of training, teaching, and research at Columbia University.  Since graduating from medical school at the University of Chicago, Dr. Pine has been engaged continuously in research on pediatric mental disorders, as reflected in more than 500 peer-reviewed papers. Currently, his group examines the degree to which pediatric mood and anxiety disorders are associated with perturbed neural circuitry function. Dr. Pine served as the Chair of the Psychopharmacologic Drug Advisory Committee for the Food and Drug Administration, Chair of the Child and Adolescent Disorders Work Group for the DSM-5 Task Force, and President of the Society of Biological Psychiatry. He is a member of the Institute of Medicine of the National Academy of Sciences and has received many other awards.

Reading List: 

Andrew H. Miller, MD

Andrew H. Miller, MD

Friday, August 3, 2018 

Inflammation and Depression: Mechanisms, Mediators and Therapeutic Implications

Andrew Miller, MD is William P. Timmie Professor of Psychiatry and Behavioral Sciences at the Emory University School of Medicine in Atlanta, Georgia. He is also the Vice Chair for Research in the Department of Psychiatry and Behavioral Sciences and Director of the Emory Behavioral Immunology Program. Finally, Dr. Miller is the co-leader of the Cancer Prevention and Control Research Program Research at the Winship Cancer Institute. Dr. Miller is an internationally recognized leader in the area of brain-immune interactions as they relate to depression in medically healthy as well as medically ill patients including patients with cancer. His work has demonstrated that during immune activation, inflammatory cytokines can access the brain and interact with the metabolism of dopamine and glutamate, while altering neurocircuits in the brain relevant to motivation and reward as well as anxiety and alarm. Dr. Miller has also studied the impact of cytokines on neuroendocrine regulation and sleep including the study of the specific signal transduction pathways involved. Additionally, Dr. Miller and his group conducted the first clinical trial examining the efficacy of a cytokine antagonist for the treatment of depression. He has produced over 200 scholarly publications and edited a book entitled Depressive Disorders and Immunity. Dr. Miller’s research awards include the Curt Richter Award from the International Society of Psychoneuroendocrinology and the Norman Cousins Award from the Psychoneuroimmunology Research Society. Aside from his research endeavors, Dr. Miller has won numerous teaching and mentoring awards and is a Board Certified Psychiatrist and past examiner for the American Board of Psychiatry and Neurology.

Reading List: 

Bunmi O. Olatunji, PhD

Bunmi O. Olatunji, PhD

Friday, June 8, 2018

The Psychopathology of Disgust in Obsessive-Compulsive Disorder

Bunmi O. Olatunji, PhD is Professor in the Department of Psychology and Psychiatry at Vanderbilt University where he also serves as the Director of Clinical Training. He is Associate Editor of the Journal of Consulting and Clinical Psychology and currently serves on the editorial boards of Behavior Therapy, International Journal of Cognitive Therapy, Journal of Obsessive-Compulsive and Related Disorders, Psychological Bulletin, Psychological Assessment, and Psychotherapy. He has published more than 160 journal articles and book chapters, and has participated in more than 100 conference presentations. He is co-author of the book “10-minute CBT: Cognitive behavioral interventions for the brief medication visit” published by Oxford Press and co-editor of the book “Disgust and its disorders: Assessment, theory, and treatment” published by the American Psychological Association.

As Director of the Emotion and Anxiety Research Laboratory at Vanderbilt University, his primary research interest involves multilevel examination of cognitive behavioral theory, assessment, and therapy for anxiety disorders. He is currently adopting an experimental psychopathology framework to examine the role of basic emotions, especially disgust, as they relate to the assessment, etiology, and maintenance of anxiety-related disorders. His research has been funded by the National Institute of Health and the Anxiety Disorders Association of America. For his research and professional efforts, he had been the recipient of the American Psychological Association (APA) Division 12 David Shakow Early Career Award for Distinguished Scientific Contributions to Clinical Psychology, the Association for the Advancement of Behavioral and Cognitive Therapies New Researcher Award, and the APA Division 12 Theodore Blau Early Career Award for Distinguished Professional Contributions to Clinical Psychology. He was also the recent recipient of the APA Distinguished Scientific Awards for an Early Career Contribution to Psychology. This award recognizes excellent psychologists who are at early stages of their research careers.

Mary Phillips, MD, MD

Mary Phillips, MD, MD

Friday, April 27, 2018

Multimodal Neuroimaging – Neural Circuits and Mood Disorders: Toward Neural Biomarkers for Novel Interventions

Mary Phillips, MD, MD is the Pittsburgh Foundation-Emmerling Endowed Chair in psychotic Disorders, and Professor in Psychiatry and Clinical and Translational Science in the University of Pittsburgh. She heads the Clinical and Translational Affective Neuroscience Program in the Department of Psychiatry at the University of Pittsburgh. Dr. Phillips’ research focuses on using multimodal neuroimaging techniques to elucidate functional and structural abnormalities in emotion processing, reward processing and emotional regulation circuitries that are associated with specific psychiatric disorders, and symptom dimensions in individuals with mood and anxiety disorders. Her research also focuses on identifying the neurodevelopmental trajectories in these circuitries that are associated with the development of such disorders in youth and infants, and the extent to which these neuroimaging techniques can identity biomarkers reflecting underlying pathophysiologic processes that denote future risk for these disorders in as yet unaffected youth. Her more recent work examines how neuromodulation techniques can be targeted on identified neural biomarkers of mood disorders, as a step toward developing new interventions for individuals with these disorders. She works in collaboration with basic neuroscientists in translational studies of neural circuitry abnormalities in these disorders.

Dr. Phillips trained in Medicine at Cambridge University, UK, and in Psychiatry at the Maudsley Hospital and the Institute of Psychiatry, King’s College, University of London, UK. She joined the Department of Psychiatry at the University of Pittsburgh as a full-time faculty member in July, 2005. In 2005, Dr. Phillips became a member of the American College of Neuropsychopharmacology; in 2006, she was awarded the Nellie Blumenthal Independent Investigator Award by the Brain and Behavior Research Foundation (National Alliance for Research in Schizophrenia and Depression); in 2012, became a Fellow of the American College of Neuropsychopharmacology; and, in 2014, she became a member of the American Society of Clinical Investigation and received the Joel Elkes Research Prize of the American College of Neuropsychopharmacology. In 2018, she became President Elect of the Society of Biological Psychiatry, has served on the Membership Committee of the American College of Neuropsychopharmacology, and on Program Committees of both the Society of Biological Psychiatry and the American College of Neuropsychopharmacology. In 2018, she was elected to the Scientific Council of the Brain and Behavior Research Foundation, and received the Brain and Behavior Research Foundation Colvin Prize for research in mood disorders in 2018.

Dr. Phillips has received research funding awards from the National Institute of Mental Health and the Brain and Behavior Research Foundation in the U.S., and the Medical Research Council and the Wellcome Trust in the UK. Dr. Phillips has mentored over 60 junior investigators, including being mentor to 11 K awardees, has extensive national and international collaborations, and has authored or co-authored more than 300 publications.

Diego Pizzagalli, PhD

Diego Pizzagalli, PhD

Friday, March 9, 2018

The Neuroscience of Major Depression: Focus on Anhedonia

Diego Pizzagalli, PhD received his M.A. (1995) and Ph.D. (1998) from the University of Zurich, Switzerland and did post-doctoral work at University of Wisconsin, Madison. From 2002-2010 he was a faculty member in the Department of Psychology at Harvard University, where he served as the John and Ruth Hazel Associate Professor of the Social Sciences. In 2010, he was recruited to McLean Hospital to serve as the Founding Director of the newly established Center for Depression, Anxiety and Stress Research (CDASR), as well as the Director of the McLean Imaging Center (MIC). Since September 2015, he also serves as the Director of Research for the Division of Depression and Anxiety. He is currently a Professor of Psychiatry at Harvard Medical School.

The main goals of his research are to improve our understanding of the psychological, environmental, and neurobiological factors associated with mood disorders, particularly major depression. To this end, he integrates behavioral, electrophysiological, neuroimaging, and, more recently, molecular genetics approaches to investigate three putative endophenotypes of depression: anhedonia (loss of pleasure), increased stress sensitivity, and negative processing biases.

Dr. Pizzagalli has published over 150 papers and chapters and serves on the editorial board of 10 journals. Among several awards, he received the Distinguished Scientific Award for an Early Career Contribution to Psychophysiology from the Society for Psychophysiological Research (2006), the Early Career Award from the EEG and Clinical Neuroscience Society (2007), the Anne M. Cataldo Excellence in Mentoring Award from McLean Hospital (2015), a MERIT award from the National Institute of Mental Health (2018), and The Stuart T. Hauser, M.D. PhD. Mentorship Award in Psychiatry from Harvard Medical School (2018).

Kerry J. Ressler, MD, PhD

Kerry J. Ressler, MD, PhD

Friday, January 12, 2018

Understanding Fear and PTSD: From Cells and Circuits to Behavior

Kerry J. Ressler, MD, PhD is the James and Patricia Poitras Chair in Psychiatry, and Chief of the Division of Depression and Anxiety Disorders at McLean Hospital, affiliate of the Harvard Medical School. Previously he spent 18 years at Emory University and Grady Memorial Hospital in Atlanta, where he led the Grady Trauma Project, a study focused on understanding the Psychology, Biology, and Trauma-Related factors contributing to Posttraumatic Stress Disorder, Substance Abuse and Violence in over 10,000 participants from urban Atlanta. He is also the 2018 President-Elect of the US Society for Biological Psychiatry. He received his Bachelor of Science degree in molecular biology from M.I.T., and his M.D./Ph.D. from Harvard Medical School. In 1992 at Harvard, he was the first student of Dr. Linda Buck (Nobel Prize, 2004), helping to identify the molecular organization of the olfactory receptor system. Dr. Ressler is a previous Investigator of the Howard Hughes Medical Institute and a current member of the National Academy of Medicine. His work focuses on translational research bridging molecular neurobiology in animal models with human genetic research on emotion, particularly fear and anxiety disorders. He has published over 230 manuscripts ranging from basic molecular mechanisms of fear processing to understanding how emotion is encoded in the brain across animal models and human patients.

Carlos Schenck, MD

Carlos Schenck, MD

Monday, December 4, 2018

What Should Psychiatrists Know About the Parasomnias?

Carlos H. Schenck was born in New York City in 1951, received his B.A. degree from the Johns Hopkins University in 1972, and his M.D. degree from the State University of New York at Buffalo in 1976. He completed a Psychiatry Residency at the University of Minnesota in 1980, where he is currently a Professor and senior staff psychiatrist at the Hennepin County Medical Center in Minneapolis. Since 1982 he has been on staff at the Minnesota Regional Sleep Disorders Center. In 1985-7 Dr. Schenck and colleagues reported on a new category of dream-enacting Parasomnia that they named REM sleep behavior disorder (RBD). In 1996 Dr. Schenck and colleagues first reported that RBD commonly heralds future parkinsonism, thus initiating a major international clinical and basic research effort in this area. In 2009 Dr. Schenck was the Founding President of the International REM Sleep Behavior Disorder Study Group that has held yearly research symposia and that has published collaborative, multicenter, peer-reviewed publications.

Dr. Schenck and colleagues also identified and named Sleep Related Dissociative Disorder in 1989; Sleep Related Eating Disorder in 1991; Status Dissociatus (mixed states of REM sleep, NREM sleep and wake in 1991; Epic Dream Disorder in 1995; Parasomnia Overlap Disorder (RBD linked comorbid with the Non-REM sleep parasomnias Sleepwalking and Sleep Terrors) in 1997;and formulated the first classification of Sexsomnia (abnormal sexual behaviors during sleep) in 2007.

Dr. Schenck and colleague Mark W. Mahowald, M.D. received the “William C. Dement Academic Achievement Award” from the American Academy of Sleep Medicine (AASM) in June 2007, for discovering RBD and other parasomnias. Drs. Schenck and Mahowald received the Sleep Research Society “Outstanding Scientific Achievement Award” in June 2010 for their discovery of RBD and other parasomnias, and also for identifying the strong link of RBD with parkinsonian disorders and with narcolepsy-cataplexy. Drs. Schenck and Mahowald received the “Sleep Science Award” from the American Academy of Neurology (AAN) during the annual AAN meeting in Boston on April 24, 2018 for their discovery of RBD and for the strong link of RBD with parkinsonian disorders.

Drs. Schenck and Mahowald identified and described the medical-legal entities “Parasomnia Pseudo-Suicide” and “Parasomnia With (Intermittent) State-Dependent Danger as a Non-Insane Automatism,” and have published extensively on the medical-legal aspects of Parasomnias. They were the founders, along with colleague Michel Cramer Bornemann, M.D. of Sleep Forensic Associates in 2007.

Dr. Schenck was Co-Chair of the Parasomnias Committee for The International Classification of Sleep Disorders-2nd Edition (ICSD-2) (AASM, 2005), and was a member of the Parasomnias Committee for the ICSD-3 published in March 2014. He is an Associate Editor of the journal Sleep, he is on the Editorial Board of the journal Sleep Science, and he is on the Executive Committee of the World Association of Sleep Medicine and the World Sleep Society. The August 2013 issue of the journal Sleep Medicine was devoted exclusively to RBD original research and review articles written by basic scientists and clinicians, with Dr. Schenck serving as a Guest Co-Editor of that issue. Dr. Schenck is the Editor of the first textbook on RBD (with 46 chapters written by clinical and basic science investigators) that will be published by Springer in early 2018.

Dr. Schenck’s first book was “Paradox Lost: Midnight in the Battleground of Sleep and Dreams” (Extreme-Nights, LLC, Minneapolis, MN, 2005). His second book was “Sleep: The Mysteries, The Problems, and The Solutions (Penguin/Avery Press, 2007). On June 3, 2011 Dr. Schenck was one of three participants in the symposium, “The Mind After Midnight: Where Do You Go When You Go To Sleep?” that took place during the 4th annual World Science Festival in New York City.

Dr. Schenck has appeared regularly on national television and radio news programs, such as CNN, ABC-TV (20/20, Good Morning America, Nightline, Prime Time [Medical Mysteries Series]), the Oprah Winfrey Show (1997, 2008), CBS-TV, NBC-TV “48 Hours”, Discovery Channel, Learning Channel, National Public Radio etc. Dr. Schenck’s research has been described in articles appearing in the New York Times, Wall Street Journal, Newsweek, National Geographic Magazine, Associated Press, US News & World Report, Reader’s Digest, and other national and international (International Herald Tribune, Stern magazine, China Times) publications.

Clint Kilts, PhD

Friday, November 10, 2018

The Acquired Brain States of Human Drug Addiction

Clint Kilts, PhD received his postgraduate trainin in psychopharmacology and neurochemistry in the Department of Pharmacology and Toxicology at Michigan State University. He continued his training in neuropharmacology, analytical neurochemistry, and human psychopharmacology in the Biological Sciences Research Center at the University of North Carolina. He subsequently joined the faculties of the Departments of Psychiatry and Pharmacology at Duke University where he served as Director of the Clinical Pscyhopharmacology Laboratory. In 1992, Dr. Kilts joined the faculty of the Department of Psychiatry and Behavioral Sciences in the Emory University School of Medicine. At Emory, he served as the Interim Director of the Center for PET and in 2000 became the first Vice Chair for Research for the Department of Psychiatry and Behavioral Sciences. In 2009, he joined faculty in the Department of Psychiatry and Behavioral Sciences in the College of Medicine at the University of Arkansas for Medical Sciences (UAMS). He is the founding director of the Brain Imaging Research Center (BIRC) in the UAMS Psychiatric Research Institute (PRI) and an Associate Director of the PRI. He has a long record of NIH-funded research, most recently in the use of in vivo brain functional, molecular, and connectivity imagingto explore the neural network processing basis of human behavior. With a focus on drug abuse and addiction, he has a clinical research focus on the use of neuroimaging technology to define the brain basis of psychiatric disorders and their treatment. Dr. Kilts received the Wilbur Mills Chair in Alcohol and Drug Abuse prevention in 2014. Additional academic accomplishments relate to organizational research planning, organization, and mentoring. His current goals as Director of the BIRC are to extend magnetic resonance imaging (MRI)-based technology and human neuroscience to areas of clinical problem solving in psychiatry and related disciplines within the PRI and at UAMS.

Amit Etkin, MD, PhD

Amit Etkin, MD, PhD

Friday, September 29, 2018

A Circuits-First Approach to Mental Illness

Amit Etkin, MD, PhD is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at Stanford, a member of the Stanford Neurosciences Institute, and an Investigator at the Palo Alto VA. He is trained both as a neuroscientist and psychiatrist. The overarching aim of the Etkin Lab is to understand the neural basis of emotional disorders and their treatment, and to leverage this knowledge to better understand how the brain works and to develop novel treatment interventions. In support of this goal, Dr. Etkin also collaborates with other neuroscientists, engineers, psychologists, physicians, and others at Stanford to establish a new intellectual, scientific, and clinical paradigm for understanding and manipulating human brain circuits in healthy individuals and for treating psychiatric disease.

Ryan Herringa, MD, PhD

Ryan Herringa, MD, PhD

Friday, August 4, 2018

Trauma, PTSD, and Neurodevelopment in Youth

Ryan Herringa, MD, PhD is an Assistant Professor in the Department of Psychiatry at the University of Wisconsin School of Medicine and Public Health. He is a pediatric psychiatrist and neuroscientist whose work explores the neural-substrates of childhood traumatic stress and PTSD. He directs the BRAVE Lab (Building Resilience after Adversity and Violent Events), which seeks to map neuro-developmental trajectories following childhood trauma. Specifically, the BRAVE Lab uses structural and functional neuro-imaging combined with behavioral, physiological, and genetic approaches to develop bio-markers of vulnerability, recovery, and resilience to childhood trauma. Bio-markers of childhood trauma could then be used to improve prevention and intervention strategies in victimized youth. In addition to his research, Dr. Herringa remains active in clinical care and teaching, with specialization in the treatment of youth with trauma-related mental illness.

Subscribe to Grand Rounds Updates

Subscribe to our newsletter to receive updates about Grand Rounds for the University of Wisconsin Psychiatry Department! We’ll keep you informed about upcoming dates, times, and speakers.

Our Grand Rounds committee appreciates your input! If you have suggestions for speakers or topics, please email Michael Koenigs, PhD at mrkoenigs@wisc.edu

Grand Rounds Planning Committee: 

  • Michael Koenigs, PhD
  • Art Walaszek, MD
  • Amber Sebastian
  • Jennifer Noll